United Therapeutics (UTHR) Tops Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
United Therapeutics (UTHR) PT Lifted to $195 at Wedbush Posts Q4
February 26, 2015 8:20 AM ESTWedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on United Therapeutics Corp. (NASDAQ: UTHR) to $195.00 (from $171.00) as Q4 and 2014 top and bottom line beat consensus estimates on strong Adcirca sales.
Moussatos commented, "Reported Q4 / 2014 revenues of $346MM/$1289MM... More
